NKG2D

NKG2D

NKG2D Informations sur la molécule

Molecule Name
NKG2-D type II integral membrane protein
Alias de la molécule
NKG2D,CD314,KLRK1,NK cell receptor D
Drug Development Progress
Nombre de médicaments cliniques9
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
Killer cell lectin-like receptor subfamily K member 1,NK cell receptor D,NKG2-D-activating NK receptor,CD314,D12S2489E,KLR,DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence,Killer Cell Lectin Like Receptor K1,NKG2-D,Killer Cell Lectin-Like Receptor Subfamily K, Member 1,KLRK1,CD314 Antigen
Contexte de la molécule
NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors, also known as KLRK1, CD314, D12S2489E, KLR and killer cell lectin like receptor K1. NKG2D itself forms a homodimer whose ectodomains serve for ligand binding. NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress such as in cancer. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity. The function of NKG2D on CD8+ T cells is to send co-stimulatory signals to activate them.

NKG2D Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
TesnatilimabIPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555Phase 2 ClinicalInnate Pharma
Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Crohn Disease; Inflammation
Details
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology)Phase 2 ClinicalChongqing Sidemu Biotechnology Technology Co Ltd
Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms
Details
NKG2D CAR-T CellPhase 1 ClinicalHangzhou Cheetah Cell Therapeutics Co Ltd
Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Ovarian Neoplasms
Details
anti-NKG2D CAR NK-cell therapy (Xinxiang Medical University)Phase 1 ClinicalXinxiang Medical University
Solid tumours
Details
Anti-NKG2D CAR-NK cells therapy (CNK Cell Therapeutics)Phase 1 ClinicalCNK Cell Therapeutics Co Ltd
Solid tumours
Details
Anti-NKG2D CAR-T cell therapy (CNK Cell Therapeutics)Phase 1 ClinicalHangzhou CNK Therapeutics Co Ltd
Pancreatic Neoplasms; Solid tumours
Details
NKG2D CAR-T Cell therapy (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd
Colorectal Neoplasms; Leukemia, Myeloid, Acute
Details
Anti-NKG2D chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)Clinical
Leukemia, Myeloid, Acute; Ovarian Neoplasms
Details
NKG2D CAR-T cell therapy (Uwell Biopharma)UWN2DClinicalUwell Biopharma
Neoplasms
Details